- Home
- TOPS vs QNCX Comparison
TOPS vs QNCX Comparison
Compare TOPS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- QNCX
- Stock Information
- Founded
- TOPS 2000
- QNCX 2012
- Country
- TOPS Greece
- QNCX United States
- Employees
- TOPS N/A
- QNCX N/A
- Industry
- TOPS Marine Transportation
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TOPS Consumer Discretionary
- QNCX Health Care
- Exchange
- TOPS Nasdaq
- QNCX Nasdaq
- Market Cap
- TOPS 40.7M
- QNCX 47.7M
- IPO Year
- TOPS 2004
- QNCX 2019
- Fundamental
- Price
- TOPS $5.45
- QNCX $1.31
- Analyst Decision
- TOPS
- QNCX Strong Buy
- Analyst Count
- TOPS 0
- QNCX 5
- Target Price
- TOPS N/A
- QNCX $8.00
- AVG Volume (30 Days)
- TOPS 302.9K
- QNCX 304.4K
- Earning Date
- TOPS 08-08-2025
- QNCX 08-12-2025
- Dividend Yield
- TOPS N/A
- QNCX N/A
- EPS Growth
- TOPS N/A
- QNCX N/A
- EPS
- TOPS 1.09
- QNCX N/A
- Revenue
- TOPS $86,127,000.00
- QNCX N/A
- Revenue This Year
- TOPS $9.90
- QNCX N/A
- Revenue Next Year
- TOPS N/A
- QNCX N/A
- P/E Ratio
- TOPS $5.06
- QNCX N/A
- Revenue Growth
- TOPS 3.83
- QNCX N/A
- 52 Week Low
- TOPS $5.00
- QNCX $0.51
- 52 Week High
- TOPS $11.68
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- TOPS 42.62
- QNCX 64.64
- Support Level
- TOPS $5.68
- QNCX $1.29
- Resistance Level
- TOPS $9.74
- QNCX $1.45
- Average True Range (ATR)
- TOPS 1.25
- QNCX 0.09
- MACD
- TOPS -0.22
- QNCX 0.03
- Stochastic Oscillator
- TOPS 12.71
- QNCX 76.74
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.